Abstract
Patients with chronic kidney disease (CKD) often have dyslipidemia that is characterized by elevated triglyceride and low HDL cholesterol levels, which spurs interest in using fibrates in this population. However, rises in serum creatinine and lowering of estimated glomerular filtration rate (eGFR) have been reported with these drugs. In this meta-analysis, researchers quantified benefits and risks associated with fibrate therapy by combining data from 10 …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
